Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
61.41
+0.56 (0.92%)
Aug 31, 2026, 4:00 PM EDT - Market closed

Royalty Pharma Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
811.99770.95858.981,13542.83619.73
Depreciation & Amortization
4.943.85--5.6723
Other Amortization
30.7928.6419.5620.521.3620.16
Asset Writedown & Restructuring Costs
69.44---615.83-
Loss (Gain) From Sale of Investments
-138.57-24.01-194.46-317.9840.2630.21
Loss (Gain) on Equity Investments
-21.05-15.69-16.22-10.0648.1253.87
Stock-Based Compensation
427.67289.892.342.362.172.44
Provision & Write-off of Bad Debts
105.97-295.84732.46560.66904.24452.84
Other Operating Activities
-1,848-1,606-1,670-1,609-2,076-1,484
Change in Accounts Receivable
3,5293,3552,9833,2012,5072,296
Change in Accounts Payable
-14.57-13.93-2.296.242.29-4.59
Change in Other Net Operating Assets
18.48-3.2255.67-0.8530.388.4
Operating Cash Flow
2,9762,4902,7692,9882,1442,018
Operating Cash Flow Growth
23.70%-10.08%-7.32%39.36%6.27%-0.84%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Acquisitions
-0.23-74.42----
Sale (Purchase) of Intangibles
-2,399-1,698-2,506-2,116-1,742-2,192
Investment in Securities
-61.5438.22-99.4557.17712.22339.82
Other Investing Activities
-53.03-280.26-72.96-14.44--18.6
Investing Cash Flow
-2,514-1,614-2,678-2,073-1,029-1,870

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-1,275-350--
Long-Term Debt Issued
-1,9541,471--1,273
Total Debt Issued
3,2293,2291,471350-1,273
Short-Term Debt Repaid
--1,275--350--
Long-Term Debt Repaid
--1,000--1,000--
Total Debt Repaid
-2,275-2,275--1,350--
Net Debt Issued (Repaid)
954.48954.481,471-1,000-1,273
Repurchase of Common Stock
-321.77-1,227-229.65-304.76--
Common Dividends Paid
-399.06-378.25-376.47-358.33-333.32-285.18
Other Financing Activities
-516.32-534.81-503.97-485.67-611.53-602.24
Financing Cash Flow
-282.68-1,186361.15-2,149-944.86385.11

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
180.08-310.33452.02-1,234169.7532.37

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-1,195-670.41-1,758-1,244-1,384-1,547
Unlevered Free Cash Flow
-993.07-500.56-1,636-1,148-1,288-1,463

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
315.55276.29159.57169.17170.14130.43
Change in Working Capital
3,5333,3383,0373,2072,5402,300
SEC Filings: 10-K · 10-Q